- Home
- SATL vs PRQR Comparison
SATL vs PRQR Comparison
Compare SATL & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.87
HOLD
Current Price
$2.04
Company Overview
Basic Information| Metric | SATL | PRQR |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.3M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SATL | PRQR |
|---|---|---|
| Price | $1.87 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | ★ 3.8M | 672.3K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $14,684,000.00 | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $1.07 |
| 52 Week High | $5.12 | $3.10 |
Technical Indicators
Market Signals| Indicator | SATL | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 42.91 |
| Support Level | $1.95 | $1.91 |
| Resistance Level | $2.25 | $2.31 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 13.33 | 21.74 |
Price Performance
Historical Comparison SATL
PRQR
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.